The secreted aspartyl proteinases of Candida albicans have long been implicated in virulence at the mucosal surface, including contributions to colonization and immunopathogenesis during vulvovaginal candidiasis. In an effort to disentangle hypha-associated virulence factor regulation from morphological transition, the purpose of this study was to determine if overexpression of SAP2 or SAP5 in an efg1Δ/Δ cph1Δ/Δ mutant could restore the capacity to cause immunopathology during murine vaginitis to this avirulent hypofilamentous strain. Two similar yet distinct genetic approaches were used to construct expression vectors to achieve SAP overexpression, and both genetic and functional assays confirmed elevated SAP activity in transformed strains. Similar to previous findings, intravaginal challenge of C57BL/6 mice with hypha-defective strains attained high levels of mucosal colonization but failed to induce robust vaginal immunopathology (neutrophil recruitment, interleukin-1 [IL-1] secretion, and lactate dehydrogenase release) compared to that with the hyphacompetent control. Moreover, constitutive expression of SAP2 or SAP5 in two distinct sets of such strains did not elicit immunopathological markers at levels above those observed during challenge with isogenic empty vector controls. Therefore, these results suggest that the physiological contributions of SAPs to vaginal immunopathology require hypha formation, other hypha-associated factors, or genetic interaction with EFG1 and/or CPH1 to cause symptomatic infection. Additionally, the outlined expression strategy and strain sets will be useful for decoupling other downstream morphogenetic factors from hyphal growth.KEYWORDS Candida, SAPs, fungal, pathogenesis, vaginitis, virulence factors, vulvovaginal V ulvovaginal candidiasis (VVC), caused by the polymorphic fungal pathogen Candida albicans, is the most prevalent human fungal infection, affecting approximately 75% of women at least once in their lifetime, primarily in their childbearing years (1). Moreover, it is estimated that roughly 5 to 8% of all women suffer from recurrent infection, defined as 3 or more symptomatic episodes per year, requiring continuous antifungal maintenance therapy to prevent infectious relapse (2). Despite its high incidence rate and the significant insight into host response mechanisms that contribute to disease pathogenesis, still relatively little is understood about the fungal virulence factors that govern symptomatic immunopathology.The clinically relevant mouse model of vaginal candidiasis, along with robust approaches to genetically manipulate C. albicans, has been an indispensable tool for